Five kinds of buyer.
DoseTrend is deliberately narrow. If you don't recognise yourself below, DoseTrend probably isn't the right tool for you, and we'll say so when we read your application.
You have one molecule in the UK market and a small market-research budget, or none. You need to answer "how are we doing this month" without waiting two weeks for a data-services request.
DoseTrend is the report you'd have built yourself if you'd had the time.
You track formulary decisions, ICB variation and the difference between primary and secondary care uptake. You need geography, and you need it defensible.
Every DoseTrend chart carries its NHSBSA source and its date, so nothing in your board pack has to be re-cited by legal.
You publish. Journals want a clean source, a stated methodology and a way to reproduce a chart from a paper. DoseTrend is built to that standard because the alternative, a personal spreadsheet, never survives peer review.
You bid NHS England's generics tenders. Hundreds of lines, a Selectt deadline, and a spreadsheet that gets rebuilt from scratch every time. For each line you want to know what trusts actually paid, who holds it now, and whether it has moved before.
The Tender Desk puts all three against every line of the schedule you import, with hospital usage for each tender region, and gives you back the workbook and the keying sheet. It comes with Molecule and Portfolio.
You cover a therapy area for a client or a portfolio company. You need one number, this month, and you need to trust it. Portfolio pricing handles three or more molecules.
The honest disqualifiers.
-
A
You need manufacturer share on a generic.The NHS doesn't publish it. No open-data tool can. You need a paid pharmaceutical data provider.
-
B
You need practice-level data outside England.Scotland, Wales and Northern Ireland come as national totals, Scotland and Wales by health board too. Practice detail, hospital data and the ICB maps are England only.
-
C
You need patient-level data.Doesn't exist in any open feed. You need CPRD, or a real-world evidence partner.